In a European study of patients comparing self-report of cannabis exposures vs synthetic cannabinoid exposures, which group was more likely to experience drowsiness, coma, agitation, seizures and bradycardia?
Synthetic canna-binoid receptor agonist presentations had statistically significantly higher rates of drowsiness, coma, agitation, seizures and bradycardia at the time of presentation.
Waters, M. L., Dargan, P. I., Yates, C., Dines, A. M., Eyer, F., Giraudon, I., … Wood, D. M. (2024). Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020. Clinical Toxicology, 62(6), 378–384. https://doi.org/10.1080/15563650.2024.2346125
Contributed by Kristine Nanagas, MD